

**Arbeiten**  
**aus der Psychiatrischen Klinik der Universität München**  
**2011**

1. **Alkelai A, Lupoli S, Greenbaum L, Giegling I, Kohn Y, Sarnier-Kanyas K, Ben-Asher E, Lancet D, Rujescu D, Macciardi F, Lerer B**  
Identification of new schizophrenia susceptibility loci in an ethnically homogeneous, family-based, Arab-Israeli sample.  
FASEB J 2011; 25: 4011-4023.
2. **Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P**  
Lamotrigine: when and where does it act in affective disorders? A systematic review.  
J Psychopharmacol 2011; 25: 1289-1294.
3. **Amico F, Meisenzahl E, Koutsouleris N, Reiser M, Möller H-J, Frodl T**  
Structural MRI correlates for vulnerability and resilience to major depressive disorder.  
J Psychiatry Neurosci 2011; 36: 15-22.
4. **Bätje C, Schläfke D, Nedopil N, Häßler F**  
Kindstötungen.  
Nervenarzt 2011; 82: 873: 79.
5. **Baghai TC, Blier P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, Kasper S, Leonard BE, Malt UF, Stein D, Versiani M, Möller H-J**  
General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.  
Eur Arch Psychiatry Clin Neurosci 2011; 261 Suppl 3: S207-S245.
6. **Baghai TC, Lieb M, Möller H-J, Bschor T, Härter M, Schauenburg H**  
Antidepressiva bei leichten depressiven Störungen.  
Psychiat Prax 2011; 38: 270-273.
7. **Baghai TC, Varallo-Bedarida G, Born C, Häfner S, Schüle C, Eser D, Rupprecht R, Bondy B, von Schacky C**  
Major depressive disorder is associated with cardiovascular risk factors

- and low Omega-3 index.  
*J Clin Psychiatry* 2011; 72: 1242-1247.
8. **Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Bürger K, Hiemeyer F, Wittmer-Rump SM, Seibyl J, Reiningger C, Sabri O**  
 Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.  
*Lancet Neurol* 2011; 10: 424-435.
  9. **Bechdorf A, Müller H, Stützer H, Wagner M, Maier W, Lautenschlager M, Heinz A, de Millas W, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Brüne M, Krüger-Özgürdal S, Wobrock T, Riedel M, Klosterkötter J**  
 Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis.  
*Schizophr Bull* 2011; 37 Suppl 2: S111-S121.
  10. **Bloss CS, Berrettini W, Bergen AW, Magistretti P, Duvvuri V, Strober M, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Keel P, Klump KL, Mitchell J, Treasure J, Woodside DB, Marzola E, Schork NJ, Kaye WH**  
 Genetic association of recovery from eating disorders: the role of GABA receptor SNPs.  
*Neuropsychopharmacology* 2011; 36: 2222-2232.
  11. **Bondy B**  
 Genetics in psychiatry: Are the promises met?  
*World J Biol Psychiatry* 2011; 12: 81-88.
  12. **Bondy B, Schwarz MJ**  
 Laborchemische Diagnostik und therapeutisches Drugmonitoring.  
 In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
*Psychiatrie Psychosomatik Psychotherapie*. Springer, Berlin Heidelberg, 2011, S. 599-620.
  13. **Boutros N, Galderisi S, Pogarell O, Riggio S**  
 Standard Electroencephalography in Clinical Psychiatry. A practical handbook.  
 Wiley-Blackwell, Chichester, 2011.

14. **Boutros N, Galderisi S, Pogarell O, Segmiller F**  
 EEG in Psychoses, mood disorders and catatonia.  
 In: Boutros N, Galderisi S, Pogarell O, Riggio S (Hrsg.)  
 Standard Electroencephalography in Clinical Psychiatry. A practical  
 handbook. Wiley-Blackwell, Chichester, 2011, S. 113-132.
  
15. **Breitling LP, Müller H, Illig T, Rujescu D, Winterer G, Dahmen N, Nitz  
 B, Raum E, Rothenbacher D, Brenner H**  
 Dopamine-related genes and spontaneous smoking cessation in ever-  
 heavy smokers.  
 Pharmacogenomics 2011; 12: 1099-1106.
  
16. **Brunnauer A, Segmiller FM, Volkamer T, Laux G, Müller N, Dehning S**  
 Cannabinoids improve driving ability in a Tourettes´ patient.  
 Psychiatry Res 2011; 190: 382.
  
17. **Buschert VC, Friese U, Teipel SJ, Schneider P, Merensky W, Rujescu  
 D, Möller H-J, Hampel H, Bürger K**  
 Effects of a newly developed cognitive intervention in amnesic mild  
 cognitive impairment and mild Alzheimer's disease: a pilot study.  
 J Alzheimers Dis 2011; 25: 679-694.
  
18. **Calati R, Porcelli S, Giegling I, Hartmann AM, Möller H-J, De Ronchi  
 D, Serretti A, Rujescu D**  
 Catechol-o-methyltransferase gene modulation on suicidal behavior and  
 personality traits: review, meta-analysis and association study.  
 J Psychiatr Res 2011; 45: 309-321.
  
19. **Carballedo A, Scheuerecker J, Meisenzahl E, Schoepf V, Bodke A,  
 Möller H-J, Doyle M, Wiesmann M, Frodl T**  
 Functional connectivity of emotional processing in depression.  
 J Affect Disord 2011; 134: 272-279.
  
20. **Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den  
 OE, Sullivan PF, Shi J, Levinson DF, Gejman PV, Sanders A, Duan J,  
 Owen MJ, Craddock NJ, O'Donovan MC, Blackman J, Lewis D, Kirov  
 GK, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V,  
 Straub RE, Weinberger DR, O'Neill FA, Walsh D, Bronstein M, Darvasi  
 A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T,  
 Ingason A, Noethen MM, Rietschel M, Cichon S, Djurovic S,  
 Andreassen OA, Cantor RM, Ophoff R, Corvin A, Morris DW, Gill M,  
 Pato CN, Pato MT, Macedo A, Gurling HM, McQuillin A, Pimm J,**

- Hultman C, Lichtenstein P, Sklar P, Purcell SM, Scolnick E, St Clair D, Blackwood DH, Kendler KS**  
GWA study data mining and independent replication identify cardiomyopathy-associated 5 (CMYA5) as a risk gene for schizophrenia. Mol Psychiatry 2011; 16: 1117-1129.
21. **Claes S, Myint A-M, Domschke K, Del-Favero J, Entrich K, Engelborghs S, de Deyn P, Müller N, Baune B, Rothermundt M**  
The kynurenine pathway in major depression: Haplotype analysis of three related functional candidate genes. Psychiatry Res 2011; 188: 355-360.
22. **Costa A, Riedel M, Müller U, Möller H-J, Ettinger U**  
Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies. Synapse 2011; 65: 998-1005.
23. **Crosby RD, Fichter MM, Quadflieg N, Wonderlich SA**  
Validating eating disorder classification models with mortality and recovery data.  
In: Striegel-Moore R, Wonderlich SA, Walsh BT, Mitchell JE (ed) Developing an Evidenced-based Classification of Eating Disorders. American Psychiatric Association, Arlington, 2011, pp. 133-144.
24. **Deckers R, Schöch H, Nedopil N, Dittmann V, Müller JL, Nowara S**  
Pflicht zur Einholung eines vorläufigen schriftlichen Gutachtens eines Psychiaters bei Anordnung einer Maßregel nach den §§ 63, 66, 66a StGB? - Zugleich Anmerkung zum Urteil des BGH vom 14.10.1999 - 2StR 205/09.  
Neue Zeitschrift für Strafrecht 2011; 31: 69-73.
25. **De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndeti DM, Newcomer JW, Uwakwe R, Asai I, Möller H-J, Gautam S, Detraux J, Correll CU**  
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.  
World Psychiatry 2011; 10: 138-151.
26. **De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller H-J, Ndeti DM, Newcomer JW,**

- Uwakwe R, Leucht S**  
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.  
World Psychiatry 2011; 10: 52-77.
27. **Dehning S, Feddersen B, Cerovecki A, Bötzel K, Müller N, Mehrkens J-H**  
Globus Pallidus internus-deep brain stimulation in Tourette's Syndrome: Can clinical symptoms predict response?  
Mov Disord 2011; 26: 2440-1.
28. **Dehning S, Feddersen B, Mehrkens JH, Müller N**  
Long-term results of electroconvulsive therapy in severe Gilles de la Tourette syndrome.  
J ECT 2011; 27: 145-147.
29. **Dong L, Bilbao A, Laucht M, Henriksson R, Yakovleva T, Ridinger M, Desrivieres S, Clarke TK, Lourdasamy A, Smolka MN, Cichon S, Blomeyer D, Treutlein J, Perreau-Lenz S, Witt S, Leonardi-Essmann F, Wodarz N, Zill P, Soyka M, Albrecht U, Rietschel M, Lathrop M, Bakalkin G, Spanagel R, Schumann G**  
Effects of the circadian rhythm gene period 1 (per1) on psychosocial stress-induced alcohol drinking.  
Am J Psychiatry 2011; 168: 1090-1098.
30. **Donohoe G, Walters J, Morris DW, Da Costa A, Rose E, Hargreaves A, Maher K, Hayes E, Giegling I, Hartmann AM, Möller H-J, Muglia P, Moskvina V, Owen MJ, O'Donovan MC, Gill M, Corvin A, Rujescu D**  
A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRG1 rs12807809.  
Schizophr Res 2011; 125: 304-306.
31. **Dow DJ, Huxley-Jones J, Hall JM, Francks C, Maycox PR, Kew JN, Gloger IS, Mehta NA, Kelly FM, Muglia P, Breen G, Jugurnauth S, Pederoso I, St Clair D, Rujescu D, Barnes MR**  
ADAMTSL3 as a candidate gene for schizophrenia: gene sequencing and ultra-high density association analysis by imputation.  
Schizophr Res 2011; 127: 28-34.
32. **Engel RR, Hennig-Fast K**  
Klinisch-psychologische und neuropsychologische Testdiagnostik.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)

- Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 569-598.
33. **Eser D, Uhr M, Leicht G, Asmus M, Länger A, Schüle C, Baghai TC, Mulert C, Rupprecht R**  
Glyoxalase-I mRNA expression and CCK-4 induced panic attacks.  
J Psychiatr Res 2011; 45: 60-63.
  34. **Ettinger U, Williams SC, Fannon D, Premkumar P, Kuipers E, Möller H-J, Kumari V**  
Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment.  
Psychopharmacology 2011; 216: 17-27.
  35. **Euteneuer F, Schwarz MJ, Hennings A, Riemer S, Stapf T, Selberdinger V, Rief W**  
Depression, cytokines and experimental pain: evidence for sex-related association patterns.  
J Affect Disord 2011; 131: 143-149.
  36. **Falkai P, Möller H-J**  
Achievement and maintenance of the new impact factor 2010.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 387-389.
  37. **Falkai P, Möller H-J**  
From generation of biomarkers to treatment and psychosocial aspects of psychosis.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 457-458.
  38. **Falkai P, Möller H**  
Mood disorder in the light of genes, comorbidity and contemporary treatment.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 531-532.
  39. **Falkai P, Möller H-J**  
The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 83-84.

40. **Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS**  
Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression.  
Biol Psychiatry 2011; 60: 804-807.
41. **Fichter M**  
Aus der Sicht des Mediziners. In: Wendt C (Hrsg.)  
Ich kann nicht anders – Eine Mutter kämpft um ihre magersüchtige Tochter. Knauer, München, 2011, S. 239-285.
42. **Fichter MM**  
Essstörungen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 887-911.
43. **Fichter MM, Meller I**  
Psychiatrische Epidemiologie.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 109-126.
44. **Fichter MM, Quadflieg N, Fischer UC**  
Severity of alcohol-related problems and mortality: results from a 20-year prospective epidemiological community study.  
Eur Arch Psychiatr Clin Neurosci 2011; 261: 293-302.
45. **Fichter MM, Quadflieg N, Nisslmüller K, Lindner S, Voderholzer U, Wunsch-Leiteritz W, Osen B, Huber T, Zahn S, Meermann R, Irrgang V, Bleichner F**  
Internetbasierte Ansätze in der Therapie von Essstörungen.  
Nervenarzt 2011; 82: 1107-1117.
46. **Finke K, Schwarzkopf W, Müller U, Frodl T, Müller HJ, Schneider WX, Engel RR, Riedel R, Möller H-J, Hennig-Fast K**  
Disentangling the adult attention-deficit hyperactivity disorder endophenotype: parametric measurement of attention.  
J Abnorm Psychol 2011; 120: 890-901.

47. **Förster S, Buschert VC, Buchholz H-G, Teipel SJ, Friese U, Zach C, la Fougère C, Rominger A, Drzezga A, Hampel H, Bartenstein P, Bürger K**  
Effects of a 6-month cognitive intervention on brain metabolism in patients with amnesic MCI and mild Alzheimer's disease.  
J Alzheimers Dis 2011; 25: 695-706.
48. **Fountoulakis KN, Möller H-J**  
Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data.  
Int J Neuropsychopharmacol 2011; 14: 405-412.
49. **Frank G, Hennig-Fast K, Klünemann HH, Schmitz G, Greenlee MW**  
Differential impact of ApoE  $\epsilon$ 4 on cortical activation during famous face recognition in cognitively intact individuals and patients with amnesic mild cognitive impairment.  
Alzheimer Dis Assoc Disord 2011; 25: 250-61.
50. **Freillinger TM, Lieb M, Schanik C, Noachtar S**  
Herpes simplex virus type 2 meningitis and symptomatic migraine.  
J Neurol 2011; 258: 689-90.
51. **Frodl T, Scheuerecker J, Schoepf V, Linn J, Koutsouleris N, Bokde AL, Hampel H, Möller H-J, Brückmann H, Wiesmann M, Meisenzahl E**  
Different effects of mirtazapine and venlafaxine on brain activation: an open randomized controlled fMRI study.  
J Clin Psychiatry 2011; 72: 448-457.
52. **Frommann I, Pukrop R, Brinkmeyer J, Bechdorf A, Ruhrmann S, Berning J, Decker P, Riedel M, Möller H-J, Wölwer W, Gaebel W, Klosterkötter J, Maier W, Wagner M**  
Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early – and additional memory dysfunction in the late – prodromal state.  
Schizophr Bull 2011; 37: 861-873.
53. **Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann, Möller H-J, German Study Group on First-Episode Schizophrenia.**  
Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention:



- results of a randomized controlled trial within the German Research Network on Schizophrenia.  
J Clin Psychiatry 2011; 72: 205-218.
54. **Giegling I, Calati R, Porcelli S, Hartmann AM, Möller H-J, De Ronchi D, Rujescu D, Serretti A**  
NCAM1, TACR1 and NOS genes and temperament: A study on suicide attempters and controls.  
Neuropsychobiology 2011; 64: 32-37.
55. **Giegling I, Drago A, Dolzan V, Plesnicar BK, Schäfer M, Hartmann AM, Sander T, Toliat MR, Möller H-J, Stassen HH, Rujescu D, Serretti A**  
Glutamatergic gene variants impact the clinical profile of efficacy and side effects of haloperidol.  
Pharmacogenet Genomics 2011; 21: 206-216.
56. **Giegling I, Drago A, Schäfer M, Hartmann AM, Sander T, Toliat MR, Möller H-J, De Ronchi D, Stassen HH, Rujescu D, Serretti A**  
Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment.  
Psychopharmacology 2011; 214: 719-728.
57. **Giegling I, Drago A, Schäfer M, Möller H-J, Rujescu D, Serretti A**  
Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects.  
Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 74-77.
58. **Gil FP, Giegling I, Reisch N, Hartmann AM, Konte B, Schwarz MJ, Rujescu D**  
Association of somatoform disorder symptoms with genetic variants potentially involved in the modulation of nociception.  
Psychiatr Genet 2011; 21: 50.
59. **Häfner S, Zierer A, Emeny RT, Thorand B, Herder C, König W, Rupprecht R, Ladwig KH for the KORA Study Investigators**  
Social isolation and depressed mood are associated with elevated serum leptin levels in men but not in women.  
Psychoneuroendocrinology 2011; 36: 300-209.

60. **Hall MH, Taylor G, Sham P, Schulze K, Rijdsdijk F, Picchioni M, Toulopoulou T, Ettinger U, Bramon E, Murray RM, Salisbury DF**  
The early auditory gamma-band response is heritable and a putative endophenotype of schizophrenia.  
Schizophr Bull 2011; 37: 778-787.
61. **Hansen T, Ingason A, Djurovic S, Melle I, Fenger M, Gustafsson O, Jakobsen KD, Rasmussen HB, Tosato S, Rietschel M, Frank J, Owen M, Bonetto C, Suvisaari J, Thygesen JH, Petursson H, Lonnqvist J, Sigurdsson E, Giegling I, Craddock N, O'Donovan MC, Ruggieri M, Cichon S, Ophoff RA, Pietilainen O, Peltonen L, Nothen MM, Rujescu D, St Clair D, Collier DA, Andreassen OA, Werge T**  
At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.  
Biol Psychiatry 2011; 70: 59-63.
62. **Haraldsson HM, Ettinger U, Sigurdsson E**  
Developments in schizophrenia genetics: from linkage to microchips, deletions and duplications.  
Nord J Psychiatry 2011; 65: 82-88.
63. **Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Riedel M, Möller H-J**  
Relationship between baseline severity of depression and antidepressant treatment outcome.  
Pharmacopsychiatry 2011; 44: 27-32.
64. **Herpertz S, Herpertz-Dahlmann B, Fichter M, Tuschen-Caffier B, Zeeck A**  
S3-Leitlinie, Diagnostik und Behandlung der Essstörungen.  
Springer, Heidelberg, 2011.
65. **Hiller G Fichter M**  
Neurotische, Belastungs- und somatoforme Störungen, Essstörungen.  
In: Klein H, Pajonk FG (Hrsg.)  
Facharztprüfung Psychiatrie und Psychotherapie. 1000 kommentierte Prüfungsfragen.  
Thieme, Stuttgart, 2011, 76-85.
66. **Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K,**

Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den BH, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, Destefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Champion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.

Nat Genet 2011; 43: 429-435.

67. **Hollweg M, Nedopil N**  
 Dokumentation in der forensischen Psychiatrie: bisherige Entwicklungen, Möglichkeiten und Grenzen der Anwendung.  
 In: Nedopil N (Hrsg)  
 Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag.  
 Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
 Pabst Science Publishers, Lengerich, 2011, S. 215-224.
68. **Ihl R, Frölich L, Winblad B, Schneider L, Burns A, Möller H-J**  
 World Federation of Societies of Biological Psychiatry (WFSBP)

- guidelines for the biological treatment of Alzheimer's disease and other dementias.  
World J Biol Psychiatry 2011; 12: 2-32.
69. **I Rankovic LM, Allen PP, Engel R, Kambeitz J, Riedel M, Müller N, Hennig-Fast**  
Attention modulation of external speech attribution in patients with hallucinations and delusions.  
Neuropsychologia 2011; 49: 805-12.
70. **Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietilainen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Moller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemenev LA, Franke B, Murray R, Vassos E, Touloupoulou T, Muhleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM**  
Copy number variations of chromosome 16p13.1 region associated with schizophrenia.  
Mol Psychiatry 2011; 16: 17-25.
71. **Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Moller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietilainen OP, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemenev LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T**  
Maternally derived microduplications at 15q11-q13: Implication of imprinted genes in psychotic illness.  
Am J Psychiatry 2011; 168: 408-417.
72. **Jonassaint CR, Szatkiewicz JP, Bulik CM, Thornton LM, Bloss C, Berrettini WH, Kaye WH, Bergen AW, Magistretti P, Strober M, Keel PK, Brandt H, Crawford S, Crow S, Fichter MM, Goldman D, Halmi KA, Johnson C, Kaplan AS, Klump KL, La Via M, Mitchell JE, Rotondo A, Treasure J, Woodside DB**  
Specific common variants of the obesity-associated FTO gene are not

- associated with psychological and behavioral eating disorder phenotypes.  
Am J Med Genet B Neuropsychiatr Genet 2011; 156B: 454-461.
73. **Juckel G, Mergl R, Brune M, Villeneuve I, Frodl T, Schmitt G, Zetsche T, Born C, Hahn K, Reiser M, Möller H-J, Bar KJ, Hegerl U, Meisenzahl EM**  
Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI.  
Cortex 2011; 47: 569-574.
74. **Kähler AK, Djurovic S, Rimol LM, Brown AA, Athanasiu L, Jonsson EG, Hansen T, Gustafsson O, Hall H, Giegling I, Muglia P, Cichon S, Rietschel M, Pietilainen OP, Peltonen L, Bramon E, Collier D, St Clair D, Sigurdsson E, Petursson H, Rujescu D, Melle I, Werge T, Steen VM, Dale AM, Matthews RT, Agartz I, Andreassen OA**  
Candidate gene analysis of the human natural killer-1 carbohydrate pathway and perineuronal nets in schizophrenia: B3GAT2 is associated with disease risk and cortical surface area.  
Biol Psychiatry 2011; 69: 90-96.
75. **Karch S, Pogarell O**  
Neurobiologie der Zwangsstörung.  
Nervenarzt 2011; 82: 299-307.
76. **Kasper S, Baghai T, Padberg F**  
Sonstige biologische Therapieverfahren - Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 767-805.
77. **Kasper S, Möller H**  
Psychopharmakotherapie - Klinisch-empirische Grundlagen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 731-766.
78. **Keeser D, Meindl T, Bor J, Palm U, Pogarell O, Mulert C, Brunelin J, Möller H-J, Reiser M, Padberg F**  
Prefrontal transcranial direct current stimulation changes connectivity of

- resting-state networks during fMRI.  
J Neurosci 2011; 31: 15284-15293.
79. **Keeser D, Padberg F, Reisinger E, Pogarell O, Kirsch V, Palm U, Karch S, Möller H-J, Nitsche MA, Mulert C**  
Prefrontal direct current stimulation modulates resting EEG and event-related potentials in healthy subjects: a standardized low resolution tomography (sLORETA) study.  
Neuroimage 2011; 55: 644-657.
80. **Kempton MJ, Ettinger U, Foster R, Williams SC, Calvert GA, Hampshire A, Zelaya FO, O'Gorman RL, McMorris T, Owen AM, Smith MS**  
Dehydration affects brain structure and function in healthy adolescents.  
Hum Brain Mapp 2011; 32: 71-79.
81. **Kempton MJ, Underwood TS, Brunton S, Stylios F, Schmechtig A, Ettinger U, Smith MS, Lovestone S, Crum WR, Frangou S, Williams SC, Simmons A**  
A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method.  
Neuroimage 2011; 58: 1051-1059.
82. **Kiefer F, Soyka M**  
Störungen durch Alkohol.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 133-162.
83. **Kienast T, Heinz A, Soyka M**  
Drogen- und Medikamentenabhängigkeit.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 163-202.
84. **Kohlboeck G, Quadflieg N, Fichter MM**  
Acting out and self-harm in children, adolescents and young adults and mental illness 18 years later: The Longitudinal Upper Bavarian Community Study.  
Eur J Psychiatry 2011; 25: 32-40.

85. **Koppel J, Campagne F, Vingtdoux V, Dreses-Werringloer U, Ewers M, Rujescu D, Hampel H, Gordon ML, Christen E, Chapuis J, Greenwald BS, Davies P, Marambaud P**  
CALHM1 P86L polymorphism modulates CSF Abeta Levels in cognitively healthy individuals at risk for Alzheimer's Disease.  
Mol Med 2011; 17: 974-979.
86. **Koychev I, Barkus E, Ettinger U, Killcross S, Roiser JP, Wilkinson L, Deakin B**  
Evaluation of state and trait biomarkers in healthy volunteers for the development of novel drug treatments in schizophrenia.  
J Psychopharmacol 2011; 25: 1207-1225.
87. **Krause D, Suh H-S, Tarassishin L, Cui QL, Durafourt BA, Choi N, Bauman A, Cosenza-Nashat M, Antel JP, Zhao M-L, Lee SC**  
The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1.  
Am J Pathol 2011; 179: 1360-72.
88. **Läge D, Egli S, Riedel M, Strauss A, Möller H-J**  
Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 3-10.
89. **Leicht G, Karch S, Karamatskos E, Giegling I, Möller H-J, Hegerl U, Pogarell O, Rujescu D, Mulert C**  
Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: Hints to a new intermediate phenotype.  
J Psychiatr Res 2011; 45: 699-705.
90. **Lennertz L, Rujescu D, Wagner M, Frommann I, Schulze-Rauschenbach S, Schuhmacher A, Landsberg MW, Franke P, Möller H-J, Wölwer W, Gaebel W, Häfner H, Maier W, Mössner R**  
Novel schizophrenia risk gene TCF4 influences verbal learning and memory functioning in schizophrenia patients.  
Neuropsychobiology 2011; 63: 131-136.
91. **Lieb M, Palm U, Hock B, Schwarz M, Domke I, Soyka M**  
Effects of alcohol consumption on iron metabolism.  
Am J Drug Alcohol Abuse 2011; 37: 68-73.

92. **Lieb M, Palm U, Nicolaus M, Reibke R, Baghai T**  
Cannabinoidinduzierte Hyperemesis.  
Psychiatr Prax 2011; 38: 147-149.
93. **Lisiecka D, Meisenzahl E, Scheuerecker J, Schoepf V, Whitty P, Chaney A, Möller H-J, Wiesmann M, Frodl T**  
Neural correlates of treatment outcome in major depression.  
Int J Neuropsychopharmacol 2011; 14: 521-34.
94. **Logan C, Nedopil N, Wolf T**  
Guidelines and standards for managing risk in mental health services.  
In: Whittington R, Logan C (eds)  
Self-Harm and violence, toward best practice in managing risk in mental health services.  
Wiley-Blackwell, Chichester, 2011, pp 145-162.
95. **Maier W, Rujescu D**  
Genetik bei psychischen Erkrankungen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 127-165.
96. **Majoie HJ, Rijkers K, Berfelo MW, Hulsman JA, Myint A, Schwarz M, Vles JS**  
Vagus nerve stimulation in refractory epilepsy: effects on pro- and anti-inflammatory cytokines in peripheral blood.  
Neuroimmunomodulation 2011; 18: 52-56.
97. **Maxwell M, Thornton LM, Root TL, Pinheiro AP, Strober M, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Keel P, Klump KL, LaVia M, Mitchell JE, Plotnicov K, Rotondo A, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**  
Life beyond the eating disorder: education, relationships, and reproduction.  
Int J Eat Disord 2011; 44: 225-232.
98. **Mechelli A, Riecher-Rössler A, Meisenzahl EM, Tognin S, Wood SJ, Borgwardt SJ, Koutsouleris N, Yung AR, Stone JM, Phillips LJ, McGorry PD, Valli I, Velakoulis D, Woolley J, Pantelis C, McGuire P**  
Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study.  
Arch Gen Psychiatry 2011; 68: 489-95.



99. **Meisenzahl E, Volz H**  
Bildgebende Verfahren.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 649-680.
100. **Meyer TD, Bernhard B, Born C, Fuhr K, Gerber S, Schaerer L,  
Langosch JM, Pfennig A, Sasse J, Scheiter S, Schottle D, van Calker D,  
Wolkenstein L, Bauer M**  
The Hypomania Checklist-32 and the Mood Disorder Questionnaire as  
screening tools - going beyond samples of purely mood-disordered  
patients.  
J Affect Disord 2011; 128: 291-298.
101. **Meyer U, Schwarz MJ, Müller N**  
Inflammatory processes in schizophrenia: a promising  
neuroimmunological target for the treatment of negative/cognitive  
symptoms and beyond.  
Pharmacol Ther 2011; 132: 96-110.
102. **Migo E, Williams SCR, Crum W, Kempton M, Ettinger U**  
The role of neuroimaging biomarkers in personalized medicine for neuro-  
degenerative and psychiatric disorders.  
In: Gordon E, Koslow SH (ed)  
Integrative Neuroscience and Personalized Medicine.  
Oxford University Press, 2011, pp. 141-163.
103. **Mittermeier V, Leicht G, Karch S, Hegerl U, Möller H-J, Pogarell O,  
Mulert C**  
Attention to emotion: auditory-evoked potentials in an emotional choice  
reaction task and personality traits as assessed by the NEO FFI.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 111-120.
104. **Möller H-J**  
Effectiveness studies: advantages and disadvantages.  
Dialogues Clin Neurosci 2011; 13: 199-207.
105. **Möller H-J**  
Evidenzbasierte Medizin zwischen Phase-III-Studien und "real world"-  
Daten.  
Psychopharmakotherapie 2011; 18: 1.

106. **Möller H-J**  
Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 1177-1191.
107. **Möller H-J**  
Ist die Validität von Arzneimittelprüfungen, die in Osteuropa  
durchgeführt werden, anzuzweifeln?  
Psychopharmakotherapie 2011; 18: 47.
108. **Möller H-J**  
Methodik empirischer Forschung.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 429-452.
109. **Möller H-J**  
Phase-III-und -IV-Studien in der Psychopharmakotherapie.  
Die Psychiatrie 2011; 8: 157-160.
110. **Möller H-J**  
Standardisierte psychiatrische Befunddiagnostik.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 545-568.
111. **Möller H-J, Falkai P**  
Pain, affect and psychotic illness.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 311-312.
112. **Möller H-J, Falkai P**  
The psychosis continuum: diagnosis and other phenotypes.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 1-2.
113. **Möller H-J, Jäger M, Riedel M, Obermeier M, Strauss A, Bottlender R**  
The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized  
patients with schizophrenic or affective disorders: Assessing courses,  
types and time stability of diagnostic classification.  
Eur Psychiatry 2011; 26: 231-243.

114. **Möller H-J, Schaub A, Riedel M**  
Schizophrene Psychosen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 213-324.
115. **Möller-Leimkühler AM**  
Geschlecht und psychische Störungen.  
Forum Public Health 2011; 71: 5-7.
116. **Möller-Leimkühler AM**  
Soziologische und sozialpsychologische Aspekte psychischer  
Erkrankungen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg,  
2011, S. 349-382.
117. **Möller-Leimkühler AM, Jandi M**  
Expressed and perceived emotion over time: does the patients' view  
matter for the caregivers' burden?  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 349-355.
118. **Möller-Leimkühler AM, Mädger F**  
Personality factors and mental health outcome in caregivers of first  
hospitalized schizophrenic and depressed patients: 2-year follow-up  
results.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 165-172.
119. **Mokros A, Neumann Cs, Stadtland C, Osterheider M, Nedopil N, Hare  
RD**  
Assessing measurement invariance of PCL-R assessments from file  
reviews of North American and German offenders.  
Int J Law Psychiatry 2011; 34: 56-63.
120. **Mühleisen TW, Basmanav FB, Forstner AJ, Mattheisen M, Priebe L,  
Herms S, Breuer R, Moebus S, Nenadic I, Sauer H, Mössner R,  
Maier W, Rujescu D, Ludwig M, Rietschel M, Nothen MM, Cichon S**  
Resequencing and follow-up of neurexin 1 (NRXN1) in schizophrenia  
patients.  
Schizophr Res 2011; 127: 35-40.

121. **Müller J, Saimeh N, Habermeyer E, Nedopil N, Schneider F, Falkai P**  
Stellungnahme der Deutschen Gesellschaft für Psychiatrie,  
Psychotherapie und Nervenheilkunde (DGPPN) zum  
Therapieunterbringungsgesetz – ThUG.  
Forensische Psychiatrie, Psychologie, Kriminologie 2011; 5: 116-118.
122. **Müller JL, Nedopil N, Saimeh N, Schneider F, Falkai P**  
Mitteilungen der DGPPN: Zur Entscheidung des  
Bundesverfassungsgerichts zu den Regelungen zur  
Sicherungsverwahrung vom 04.05.2011.  
Nervenarzt 2011; 82: 933-35.
123. **Müller N, Myint AM, Schwarz MJ**  
Inflammatory biomarkers and depression.  
Neurotox Res 2011; 19: 308-318.
124. **Müller N, Myint AM, Schwarz MJ**  
Kynurenine pathway in schizophrenia: pathophysiological and  
therapeutic aspects.  
Curr Pharm Des 2011; 17: 130-136.
125. **Müller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson  
MM, Visser-Vandewalle V**  
European clinical guidelines for Tourette syndrome and other tic  
disorders. Part IV: deep brain stimulation.  
Eur Child Adolesc Psychiatry 2011; 20: 209-217.
126. **Muhtz C, Zyriax BC, Bondy B, Windler E, Otte C**  
Association of a common mineralocorticoid receptor gene polymorphism  
with salivary cortisol in healthy adults.  
Psychoneuroendocrinology 2011; 36: 298-301.
127. **Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I,  
Arolt V, Müller N**  
Elevated macrophage migration inhibitory factor and decreased  
transforming growth factor-beta levels in major depression - no influence  
of celecoxib treatment.  
J Affect Disord 2011; 134: 217-225.
128. **Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpe S,  
Steinbusch HW, Leonard BE, Kim YK**

- Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naive and medication-free schizophrenic patients.  
Brain Behav Immun 2011; 25: 1576-1581.
129. **Nedopil N**  
Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag. Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
Pabst Science Publishers, Lengerich, 2011.
130. **Nedopil N**  
Forensische Psychiatrie.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 1593-1632.
131. **Nedopil N**  
Forensische Psychiatrie und empirische Forschung.  
In: Nedopil N (Hrsg.)  
Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag. Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
Pabst Science Publishers, Lengerich, 2011, S. 24-40.
132. **Nedopil N**  
Freiraum für den menschlichen Willen – Gedanken zu einem überflüssigen und unlösbaren Disput.  
In: Nedopil N (Hrsg.)  
Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag. Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
Pabst Science Publishers, Lengerich, 2011, S. 254-270.
133. **Nedopil N, Wittmann S**  
Von der empirischen Wahrscheinlichkeit zur juristischen Entscheidung – Risikomanagement im forensischen Dialog.  
In: Heer M, Heimgartner S, Niggli MA, Thommen M (Hrsg.)  
Toujours agité – jamais abattu. Festschrift für Hans Wiprächtiger. Helbig-Lichterhahn, Basel, 2011, S. 237-250.

134. **Nothdurfter C, Tanasic S, Rammes G, Rupprecht R**  
Modulation of ligand-gated ion channels as a novel pharmacological principle.  
Pharmacopsychiatry 2011; 44 Suppl 1: S27-S34.
135. **Obermeier M, Schennach-Wolff R, Meyer S, Möller H-J, Riedel M, Krause D, Seemüller F**  
Is the PANSS used correctly? a systematic review.  
BMC Psychiatry 2011; 11: 113.
136. **Okusaga O, Langenberg P, Sleemi A, Vaswani D, Giegling I, Hartmann AM, Konte B, Friedl M, Groer MW, Yolken RH, Rujescu D, Postolache TT**  
Toxoplasma gondii antibody titers and history of suicide attempts in patients with schizophrenia.  
Schizophr Res 2011; 133: 150-155.
137. **Owen DR, Lewis AJ, Reynolds R, Rupprecht R, Eser D, Wilkins MR, Bennacef I, Nutt DJ, Parker CA**  
Variation in binding affinity of the novel anxiolytic SBD173 for hte 18 kDa translocstor protein in human brain.  
Synapse 2011; 65: 257-59.
138. **Palm U**  
Von der Schizophrenie zum Saliience-Syndrom. Alter Wein in neuen Schläuchen?  
Nervenheilkunde 2011; 30: 819-821.
139. **Palm U, Forsthoff A, de la Fontaine F, Rupprecht T, Karch S, Meisenzahl EM, Pogarell O**  
Electroconvulsive therapy and corpus callosum aplasia: a case report.  
J ECT 2011; 27: e17-e20.
140. **Palm U, Geiger J, Lieb M**  
Emergence delirium after propofol anaesthesia.  
Eur J Clin Pharmacol 2011; 67: 209-210.
141. **Palm U, Möller H-J**  
Reception of Kraepelin's ideas 1900-1960.  
Psychiatry Clin Neurosci 2011; 65: 318-325.

142. **Palm U, Strauss A, Born C, Pogarell O**  
Electroconvulsive therapy and corpus callosum aplasia: a 3 year follow-up.  
Case Reports in Psychiatry 2011; 638506.
143. **Perkins AM, Ettinger U, Williams SC, Reuter M, Hennig J, Corr PJ**  
Flight behaviour in humans is intensified by a candidate genetic risk factor for panic disorder: evidence from a translational model of fear and anxiety.  
Mol Psychiatry 2011; 16: 242-244.
144. **Pogarell O**  
Abnormal Patterns.  
In: Boutros N, Galderisi S, Pogarell O, Riggio S (Hrsg.)  
Standard Electroencephalography in Clinical Psychiatry. A practical handbook. 2011, S. 59-76.
145. **Pogarell O**  
EEG Recording and Analysis.  
In: Boutros N, Galderisi S, Pogarell O, Riggio S (Hrsg.)  
Standard Electroencephalography in Clinical Psychiatry. A practical handbook. Wiley-Blackwell, Chichester, 2011, S. 13-31.
146. **Pogarell O, Hegerl U**  
Neurophysiologische Untersuchungsmethoden.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 621-647.
147. **Pogarell O, Karch S, Leicht G, Mulert C**  
Elektroenzephalographie (EEG) und EEG-fMRT-Kombination.  
In: Schiepek G  
Neurobiologie der Psychotherapie. Schattauer, Stuttgart, 2011, S. 61-72.
148. **Pogarell O, Padberg F, Karch S, Segmiller F, Juckel G, Mulert C, Hegerl U, Tatsch K, Koch W**  
Dopaminergic mechanisms of target detection - P300 event related potential and striatal dopamine.  
Psychiatry Res 2011; 194: 212-218.

149. **Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bjorklund A, Lindvall O, Piccini P**  
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio.  
Mov Disord 2011; 26: 1997-2003.
150. **Preuss UW, Ridinger M, Rujescu D, Samochowiec J, Fehr C, Wurst FM, Koller G, Bondy B, Wodarz N, Debniak T, Grzywacz A, Soyka M, Zill P**  
Association of ADH4 genetic variants with alcohol dependence risk and related phenotypes: results from a larger multicenter association study.  
Addict Biol 2011; 16: 323-333.
151. **Quednow BB, Ettinger U, Mössner R, Rujescu D, Giegling I, Collier DA, Schmechtig A, Kühn KU, Möller H-J, Maier W, Wagner M, Kumari V**  
The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers.  
J Neurosci 2011; 31: 6684-6691.
152. **Reyes-Rodriguez ML, Von Holle A, Ullman TF, Thornton LM, Klump KL, Brandt H, Crawford S, Fichter MM, Halmi KA, Huber T, Johnson C, Jones I, Kaplan AS, Mitchell JE, Strober M, Treasure J, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**  
Posttraumatic stress disorder in anorexia nervosa.  
Psychosom Med 2011; 73: 491-497.
153. **Riedel M, Möller H-J, Obermeier M, Adli M, Bauer M, Kronmüller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemüller F**  
Clinical predictors of response and remission in inpatients with depressive syndromes.  
J Affect Disord 2011; 133: 137-149.
154. **Riedel M, Seemüller F, Musil R, Spellmann I, Möller H-J, Schennach-Wolff R**  
Early improvement and its predictive validity in first-schizophrenia patients.  
In: Ritsner, MS (Hrsg.)  
Handbook of Schizophrenia Spectrum Disorders. Volume III.  
Springer, Dordrecht Heidelberg, 2011, S. 93-108.



155. **Riedel M, Seemüller F, Schennach-Wolff R, Musil R, Spellmann U, Oppolzer B, Möller H, Köhler J, Severus E**  
Wirksamkeit und Verträglichkeit von Quetiapin im klinischen Alltag. Analyse einer Anwendungsbeobachtung bei Patienten mit schizophrenen Störungen in Deutschland (CLINPEP).  
Psychopharmakotherapie 2011; 18: 75-83.
156. **Riedel M, Severus E, Schennach-Wolff R, Musil R, Spellmann I, Oppolzer B, Möller H-J, Köhler J, Seemüller F**  
Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a German clinical-practice evaluation programme.  
J Clin Psychopharmacol 2011; 31: 120-122.
157. **Riedel M, Spellmann I, Schennach-Wolff R, Obermeier M, Musil R**  
The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia.  
Qual Life Res 2011; 20: 263-272.
158. **Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jonsson EG, Bitter I, Pietilainen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Borglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jurgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lonqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nothen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft**

- TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Rethelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den OE, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV**  
Genome-wide association study identifies five new schizophrenia loci.  
Nat Genet 2011; 43: 969-976.
159. **Root TL, Szatkiewicz JP, Jonassaint CR, Thornton LM, Pinheiro AP, Strober M, Bloss C, Berrettini W, Schork NJ, Kaye WH, Bergen AW, Magistretti P, Brandt H, Crawford S, Crow S, Fichter MM, Goldman D, Halmi KA, Johnson C, Kaplan AS, Keel PK, Klump KL, La Via M, Mitchell JE, Rotondo A, Treasure J, Woodside DB, Bulik CM**  
Association of candidate genes with phenotypic traits relevant to anorexia nervosa.  
Eur Eat Disord Rev 2011; 19: 487-493.
160. **Rujescu D**  
Are we going to end up with many distinct genomic syndromes in psychiatry?  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 145-146.
161. **Rujescu D**  
New genetic findings in schizophrenia.  
Eur Arch Psychiatry Clin Neurosci 2011; 261 Suppl 1: S31-S32.
162. **Rupprecht R, Müller N**  
Psychoneuroendokrinologische und psychoneuroimmunologische Grundlagen psychischer Erkrankungen.  
In: Möller H, Laux G, Kapfhammer H (Hrsg.)  
Psychiatrie Psychosomatik Psychotherapie. Springer, Berlin Heidelberg, 2011, S. 251-276.
163. **Samson AC, Meisenzahl E, Scheuerecker J, Rose E, Schoepf V, Wiesmann M, Frodl T**  
Brain activation predicts treatment improvement in patients with major depressive disorder.  
J Psychiatr Res 2011; 45: 1214-22.

164. **Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlosser R, Schneider F, Gaebel W, Seemüller F, Möller H-J, Riedel M**  
 Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - Is it all about early response?  
 Eur Neuropsychopharmacol 2011; 21: 370-378.
165. **Schennach-Wolff R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller H-J, Riedel M**  
 Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.  
 J Psychiatr Res 2011; 45: 1639-1647.
166. **Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller H-J, Riedel M**  
 Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale.  
 Acta Psychiatr Scand 2011; 123: 228-238.
167. **Schennach-Wolff R, Seemüller F, Musil R, Spellmann I, Möller H-J, Riedel M**  
 Suicidality an outcome in schizophrenia patients.  
 In: Ritsner, MS (Hrsg.)  
 Handbook of Schizophrenia Spectrum Disorders. Volume III.  
 Springer Dordrecht Heidelberg, 2011, S. 365-382.
168. **Schennach-Wolff R, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Buchkremer G, Gastpar M, Jäger M, Möller H-J, Riedel M**  
 Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders.  
 Eur Psychiatry 2011; 26: 284-292.
169. **Schiepeck G, Heinzl S, Karch S**  
 Die neurowissenschaftliche Erforschung der Psychotherapie.  
 In: Schiepeck G. Neurobiologie der Psychotherapie.  
 Schattauer, Stuttgart, 2011, S. 1-34.

170. **Schiepek G, Karch S, Tominschek I, Pogarell O**  
Zwangsstörungen.  
In: Schiepek G. Neurobiologie der Psychotherapie.  
Schattauer, Stuttgart, 2011, S. 405-32.
171. **Schmidt P, Helten C, Soyka M**  
Predictive value of obsessive-compulsive drinking scale (OCDS) for  
outcome in alcohol-dependent inpatients: results of a 24-month follow-up  
study.  
Subst Abuse Treat Prev Policy 2011; 6: 14.
172. **Schneider P, Bürger K, Teipel S, Uspenskaya O, Hartmann O,  
Hansson O, Minthon L, Rujescu D, Möller H-J, Zetterberg H,  
Blennow K, Ernst A, Bergmann A, Hampel H**  
Antihypertensive therapy is associated with reduced rate of conversion to  
Alzheimer's disease in midregional proatrial natriuretic peptide stratified  
subjects with mild cognitive impairment.  
Biol Psychiatry 2011; 70: 145-151.
173. **Schüle C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R**  
Neuroactive steroids in affective disorders: target for novel  
antidepressant or anxiolytic drugs?  
Neuroscience 2011; 191: 55-77.
174. **Seemüller F, Baghai TC, Möller H-J**  
Pharmakotherapie der Depression.  
Psychotherapie 2011; 16: 267-276.
175. **Seemüller F, Lewitzka U, Möller H-J**  
In people taking antidepressants, suicidal behaviour is less common  
when they are taking them than in unexposed periods.  
Evid Based Ment Health 2011; 14: 98.
176. **Shi Y, Li Z, Xu Q, Wang T, Li T, Shen J, Zhang F, Chen J, Zhou G, Ji W,  
Li B, Xu Y, Liu D, Wang P, Yang P, Liu B, Sun W, Wan C, Qin S, He G,  
Steinberg S, Cichon S, Werge T, Sigurdsson E, Tosato S, Palotie A,  
Nothen MM, Rietschel M, Ophoff RA, Collier DA, Rujescu D, Clair DS,  
Stefansson H, Stefansson K, Ji J, Wang Q, Li W, Zheng L, Zhang H,  
Feng G, He L**  
Common variants on 8p12 and 1q24.2 confer risk of schizophrenia.  
Nat Genet 2011; 43: 1224-1227.

177. **Soyka M**  
 Aggression und gewalttätiges Verhalten bei Schizophrenie - Prävalenz, klinische Korrelate und neurobiologische Grundlagen.  
 In: Nedopil N (Hrsg.)  
 Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag. Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München. Pabst, 2011, S. 317-330.
178. **Soyka M**  
 Alkoholabhängigkeit. Diagnostik und Therapie.  
 neuropsy 2011; 4: 15-19.
179. **Soyka M**  
 Neurobiology of aggression and violence in schizophrenia.  
 Schizophr Bull 2011; 5: 913-920.
180. **Soyka M**  
 Neuro Doping.  
 In: Spitzer G, Franke E (Hrsg.)  
 Sport, Doping und Enhancement – Transdisziplinäre Perspektiven. Sportverlag Strauß, Köln, 2011, S. 225-234.
181. **Soyka M**  
 Pharmakotherapie der Alkoholabhängigkeit.  
 Schweiz Arch Neurol Neurochir Psychiatr 2011; 162: 268-277.
182. **Soyka M**  
 Psychiatrie und Humor. Eine Spurensuche.  
 Pro Mente Sana aktuell 2011; 4: 27-28.
183. **Soyka M, Baumgärtner G, Zingg C**  
 Prevalence of delusional disorder among psychiatry inpatients: data from the german hospital register.  
 Neuropsychiatry 2011; 1: 319-23.
184. **Soyka M, Kranzler HR, van den BW, Krystal J, Möller H-J, Kasper S**  
 The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.  
 World J Biol Psychiatry 2011; 12: 160-187.

185. **Soyka M, Limmer C, Lehnert R, Koller G, Martin G, Kufner H, Kagerer S, Haberthur A**  
A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study.  
Am J Drug Alcohol Abuse 2011; 37: 497-508.
186. **Soyka M, Schmidt P**  
Prevalence of delusional jealousy in psychiatric disorders.  
J Forensic Sci 2011; 56: 450-452.
187. **Soyka M, Schmidt P, Helten C**  
Predictive value of Obsessive-Compulsing Drinking Scale (OCDS) for outcome in alcohol-dependent inpatients: results of a 24-month follow-up study.  
Subst Abus Treat Prev Policy 2011; 6: 14.
188. **Soyka M, Träder A, Klotsche J, Backmund M, Buhringer G, Rehm J, Wittchen HU**  
Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study.  
J Clin Psychopharmacol 2011; 31: 678-680.
189. **Soyka M, Zingg C, Baumgärtner G**  
Prevalence of delusional disorder among psychiatric inpatients: data from the German hospital register.  
Neuropsychiatry 2011; 1: 319-323.
190. **Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller H-J, Riedel M**  
Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients.  
J Psychiatr Res 2011; 45: 234-241.
191. **Sperling W, Biermann T, Spannenberger R, Clepce M, Padberg F, Reulbach U, Kornhuber J, Thuerlauf N**  
Changes in gustatory perceptions of patients with major depression treated with vagus nerve stimulation (VNS).  
Pharmacopsychiatry 2011; 44: 67-71.

192. **Stassen H, Anghelescu IG, Angst J, Boker H, Lotscher K, Rujescu D, Szegedi A, Scharfetter C**  
Predicting response to psychopharmacological treatment: survey of recent results.  
Pharmacopsychiatry 2011; 44: 263-272.
193. **Steiger H, Fichter M, Bruce KR, Joober R, Badawi G, Richardson J, Groleau P, Ramos C, Israel M, Bondy B, Quadflieg N, Bachetzky N**  
Molecular-genetic correlates of self-harming behaviors in eating-disordered women: findings from a combined Canadian-German sample.  
Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 102-106.
194. **Steinberg S, de Jong S, Andreassen OA, Werge T, Borglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietilainen OP, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lonqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E, Jurgens G, Glenthøj B, Terenius L, Hougaard DM, Orntoft T, Wiuf C, Didriksen M, Hollegaard MV, Nordentoft M, van Winkel R, Kenis G, Abramova L, Kaleda V, Arrojo M, Sanjuan J, Arango C, Sperling S, Rossner M, Ribolsi M, Magni V, Siracusano A, Christiansen C, Kiemeneý LA, Veldink J, van den BL, Ingason A, Muglia P, Murray R, Nothen MM, Sigurdsson E, Petursson H, Thorsteinsdottir U, Kong A, Rubino IA, De Hert M, Rethelyi JM, Bitter I, Jonsson EG, Golimbet V, Carracedo A, Ehrenreich H, Craddock N, Owen MJ, O'Donovan MC, Ruggeri M, Tosato S, Peltonen L, Ophoff RA, Collier DA, St Clair D, Rietschel M, Cichon S, Stefansson H, Rujescu D, Stefansson K**  
Common variants at VRK2 and TCF4 conferring risk of schizophrenia.  
Hum Mol Genet 2011; 20: 4076-4081.
195. **Steinberg S, Mors O, Borglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Bottcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietilainen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonqvist J, Paunio T, Hartmann A, Jurgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Moller HJ, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Rethelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeneý LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K**

- Expanding the range of ZNF804A variants conferring risk of psychosis.  
Mol Psychiatry 2011; 16: 59-66.
196. **Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein H-G, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer zu Schwabedissen L, Bogerts B, Myint A-M**  
Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?  
J Neuroinflammation 2011; 8: 94.
197. **Stergiakouli E, Langley K, Williams H, Walters J, Williams NM, Suren S, Giegling I, Wilkinson LS, Owen MJ, O'Donovan MC, Rujescu D, Thapar A, Davies W**  
Steroid sulfatase is a potential modifier of cognition in attention deficit hyperactivity disorder.  
Genes Brain Behav 2011; 10: 334-344.
198. **Stickel F, Buch S, Lau K, zu Schwabedissen HM, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F, Hinrichsen H, Günther R, Arlt A, Seeger M, Müller S, Seitz HK, Soyka M, Lerch M, Lammert F, Sarrazin C, Kubitz R, Haussinger D, Hellerbrand C, Broring D, Schreiber S, Kiefer F, Spanagel R, Mann K, Datz C, Krawczak M, Wodarz N, Volzke H, Hampe J**  
Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians.  
Hepatology 2011; 53: 86-95.
199. **Stübner S, Grohmann R, Rüter E, Möller H-J**  
Ändert sich die Anwendungshäufigkeit nach Ablauf des Patentschutzes der Originalpräparate?  
Psychopharmakotherapie 2011; 18: 123-126.
200. **Stübner S, Nedopil N**  
Ambulante Sicherungsnachsorge – Beleituntersuchung eines forensischen Modellprojektes in Bayern.  
In: Nedopil N (Hrsg)  
Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag.  
Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
Pabst Science Publishers, Lengerich, 2011, S. 248-253.



201. **Teipel SJ, Meindl T, Grinberg L, Grothe M, Cantero JL, Reiser MF, Möller H-J, Heinsen H, Hampel H**  
The cholinergic system in mild cognitive impairment and Alzheimer's disease: an in vivo MRI and DTI study.  
Hum Brain Mapp 2011; 32: 1349-62.
202. **Tretter F, Gebicke-Haerter PJ, an der Heiden U, Rujescu D, Mewes HW, Turck CW**  
Affective disorders as complex dynamic diseases - a perspective from systems biology.  
Pharmacopsychiatry 2011; 44 Suppl: S2-S8.
203. **Tretter F, Rujescu D, Turck CW, Mewes HW**  
Computational Neuropsychiatry Vol. 6: Systems Biology of Affective Disorders. Editorial.  
Pharmacopsychiatry 2011; 44 Suppl 1: S1.
204. **Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O'Donovan MC**  
Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder.  
Mol Psychiatry 2011; 16: 429-441.
205. **Yates DB, Dittmann S, Kapczinski F, Trentini CM**  
Cognitive abilities and clinical variables in bipolar I depressed and euthymic patients and controls.  
J Psychiatr Res 2011; 45: 495-504.
206. **Yundina E, Nedopil N**  
Indirekte Diagnostik pädosexueller Neigungen.  
In: Nedopil N (Hrsg)  
Die Psychiatrie und das Recht - Abgrenzung und Brückenschlag. Jubiläumsschrift zum vierzigjährigen Bestehen der Abteilung für Forensische Psychiatrie der Psychiatrischen Klinik der Universität München.  
Pabst Science Publishers, Lengerich, 2011, S. 271-282.

207. **Zhang F, Chen Q, Ye T, Lipska BK, Straub RE, Vakkalanka R, Rujescu D, St Clair D, Hyde TM, Bigelow L, Kleinman JE, Weinberger DR**  
Evidence of sex-modulated association of ZNF804A with schizophrenia.  
Biol Psychiatry 2011; 69: 914-917.
208. **Zill P, Preuss UW, Koller G, Bondy B, Soyka M**  
Lack of association between SNPs in the NEUROD2 gene and alcohol dependence in a German patient sample.  
Psychiatry Res 2011; 187: 220-223.
209. **Zill P, Vielsmeier V, Büttner A, Eisenmenger W, Siedler F, Scheffer B, Möller H-J, Bondy B**  
Postmortem proteomic analysis in human amygdala of drug addicts: possible impact of tubulin on drug-abusing behavior.  
Eur Arch Psychiatry Clin Neurosci 2011; 261: 121-131.
210. **Zucker N, Von Holle A, Thornton LM, Strober M, Plotnicov K, Klump KL, Brandt H, Crawford S, Crow S, Fichter MM, Halmi KA, Johnson C, Kaplan AS, Keel P, LaVia M, Mitchell JE, Rotondo A, Woodside DB, Berrettini WH, Kaye WH, Bulik CM**  
The significance of repetitive hair-pulling behaviors in eating disorders.  
J Clin Psychol 2011; 67: 391-403.